
Home » Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine
Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine
November 5, 2013
U.S.-based biopharmaceutical company Nanotherapeutics has started enrollment of first patient in a Phase II cervical cancer trial for Triapine, a ribonucleotidereductase inhibitor.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
15Apr
-
21Apr
-
26Apr
-
06May